| 1 |
Pfizer’s TALA (talazoparib) in metastatic castration-resistant prostate cancer (mCRPC) |
0.8 |
Visit Page
|
| 2 |
AstraZeneca and Merck’s Lynparza (olaparib) in Metastatic Castration-resistant Prostate Cancer (mCRPC) |
0.8 |
Visit Page
|
| 3 |
Bayer Healthcare and Orion's Nubeqa (darolutamide) in Non-metastatic castration-resistant prostate cancer (nmCRPC) |
0.8 |
Visit Page
|
| 4 |
Roche’s Ipatasertib (RG7440) in Metastatic Castration-resistant Prostate Cancer (mCRPC) |
0.8 |
Visit Page
|
| 5 |
GSK has a strong say in ASCO 2020 as they are announcing key data on Cell Therapy and Next-generation Immuno-oncology |
0.8 |
Visit Page
|
| 6 |
Can much awaited JAVELIN data give any surprise in ASCO 2020? |
0.8 |
Visit Page
|
| 7 |
Another new combination approaches for front line multiple myeloma may bring a new option to patients |
0.8 |
Visit Page
|
| 8 |
How effectively microsatellite instability-high/mismatch repair can be used for proper positioning in the Colorectal Cancer treatment landscape? |
0.8 |
Visit Page
|
| 9 |
Another win for blockbuster Osimertinib (in an early stage of EGFR NSCLC) will further strengthen its potential in Lung Cancer |
0.8 |
Visit Page
|
| 10 |
KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative... |
0.8 |
Visit Page
|
| 11 |
Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)... |
0.8 |
Visit Page
|
| 12 |
PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2... |
0.8 |
Visit Page
|
| 13 |
Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOT... |
0.8 |
Visit Page
|
| 14 |
Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, doubleblinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breas... |
0.8 |
Visit Page
|
| 15 |
A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triplenegative breast cancer (mTNBC) (ENHANCE 1). |
0.8 |
Visit Page
|
| 16 |
Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer. |
0.8 |
Visit Page
|
| 17 |
A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer. |
0.8 |
Visit Page
|
| 18 |
SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC)... |
0.8 |
Visit Page
|
| 19 |
Preliminary safety, efficacy and pharmacokinetics (PK) results of KN026, a HER2 bispecific antibody in patients (pts) with HER2-positive metastatic breast cancer. |
0.8 |
Visit Page
|
| 20 |
A phase Ib study of abemaciclib in combination with pembrolizumab for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metas... |
0.8 |
Visit Page
|
| 21 |
Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (H... |
0.8 |
Visit Page
|
| 22 |
Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast canc... |
0.8 |
Visit Page
|
| 23 |
Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: (DART=Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors) (SWOG S1609, Cohort 36). |
0.8 |
Visit Page
|
| 24 |
A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlatio... |
0.8 |
Visit Page
|
| 25 |
A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC) |
0.8 |
Visit Page
|
| 26 |
IMvigor130 results might support the usage of combination of atezolizumab +/- platinum/gemcitabine as an important new treatment option for patients with untreated mUC. |
0.8 |
Visit Page
|
| 27 |
Another missed trial of the ASCO 2020 as Adjuvant treatment with the PD-L1 inhibitor did not significantly improve disease-free survival (DFS) in patients with muscle-invasive bladder cancer |
0.8 |
Visit Page
|
| 28 |
Promising results from IMbrave150 TRIAL of Atezolizumab + Bevacizumab may shift the treatment paradigsm for advanced HCC |
0.8 |
Visit Page
|
| 29 |
Good clinical response for dual immune checkpoint inhibitors (Tremelimumab + Durvalumab) in second line HCC however, tough fight ahead in first line setting from much promising Atezolizumab + Bevacizu... |
0.8 |
Visit Page
|
| 30 |
Long term follow up of Lifileucel treatment in a heavily pretreated metastatic melanoma patients who progressed on multiple prior therapies, including anti-PD1 and BRAF/MEK inhibitors |
0.8 |
Visit Page
|
| 31 |
Future directions for Head and Neck treatment based on TMB studies |
0.8 |
Visit Page
|
| 32 |
Long term follow up study of the use of pembrolizumab and its combination as first line treatment for recurrent/metastatic head and neck cancer |
0.8 |
Visit Page
|
| 33 |
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irino... |
0.8 |
Visit Page
|
| 34 |
Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longerterm follow-up of the phase II, KEYNOTE-164 study. |
0.8 |
Visit Page
|
| 35 |
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical... |
0.8 |
Visit Page
|
| 36 |
A Phase II, multicenter, open-label study of trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer |
0.8 |
Visit Page
|
| 37 |
Interim analysis of ZUMA-5: A phase II study of axi-cel in pts with R/R iNHL |
0.8 |
Visit Page
|
| 38 |
Lisocabtagene maraleucel (liso-cel) for treatment of 2L TNE R/R aggressive large B-cell NHL |
0.8 |
Visit Page
|
| 39 |
Effect of enasidenib plus azacitidine (AZA) on Complete and overall response versus AZA monotherapy in mutant-IDH2 newly diagnosed AML |
0.8 |
Visit Page
|
| 40 |
Tolerability and efficacy of anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML: Phase Ib results |
0.8 |
Visit Page
|
| 41 |
Glasdegib plus low-dose cytarabine in AML or MDS: BRIGHT AML 1003 final report and four-year OS follow-up |
0.8 |
Visit Page
|
| 42 |
Five year results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML |
0.8 |
Visit Page
|
| 43 |
6 month update: Phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with AML (VIALE-C) |
0.8 |
Visit Page
|
| 44 |
Long-term survivors and gilteritinib safety post 1 year in FLT3-mutated R/R AML: ADMIRAL trial |
0.8 |
Visit Page
|
| 45 |
Glasdegib in combination with azacitidine in patients with untreated higher-risk MDS, AML and CMML: Effects on marrow recovery and transfusion independence |
0.8 |
Visit Page
|
| 46 |
CC-486 is safe and well-tolerated as maintenance therapy in patients >75 years with AML in first remission following induction chemotherapy: Phase III QUAZAR AML-001 trial |
0.8 |
Visit Page
|
| 47 |
HRQoL in the phase III QUAZAR-AML-001 trial of CC-486 as maintenance therapy for patients with AML in first remission following induction chemotherapy |
0.8 |
Visit Page
|
| 48 |
Venetoclax + intensive chemo with CLIA achieves high rates of durable complete remission with low rates of MRD in pts with newly diagnosed AML |
0.8 |
Visit Page
|
| 49 |
Phase II study of lower-dose pracinostat plus azacitidine safety and efficacy in patients with high/very high-risk MDS |
0.8 |
Visit Page
|
| 50 |
Phase I study of teclistamab, a dual-targeting immunotherapeutic, in relapse/refractory Multiple Myeloma |
0.8 |
Visit Page
|
| 51 |
Initial results from phase III BOSTON study, comparing weekly selinexor + Vd versus twice weekly Vd in patients with R/R multiple myeloma |
0.8 |
Visit Page
|
| 52 |
Initial KarMMa results : bb2121, a BCMA-targeted CAR T-cell therapy, in R/R multiple myeloma patients |
0.8 |
Visit Page
|
| 53 |
Phase 1/2 update from EVOLVE study : orva-cel, a BCMA- directed CAR T cell therapy for patients with R/R multiple myeloma |
0.8 |
Visit Page
|
| 54 |
Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of antiCD22 activity |
0.8 |
Visit Page
|
| 55 |
Safety and efficacy results of GC027: The first-in-human, universal CART cell therapy for adult r/r T-ALL |
0.8 |
Visit Page
|
| 56 |
Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a BCMA-directed CAR-T-cell therapy, in R/R multiple myeloma |
0.8 |
Visit Page
|
| 57 |
Primary analysis of phase II trial of VRd with/without elotuzumab for newly diagnosed multiple myeloma (SWOG-1211). |
0.8 |
Visit Page
|
| 58 |
Depth of response to isatuximab + KRd (Isa-KRd) in front-line treatment of multiple myeloma: Interim analysis of the GMMG-CONCEPT trial |
0.8 |
Visit Page
|
| 59 |
Updates from BELLINI, a phase III study of venetoclax or placebo in combination with Vd in R/R multiple myeloma |
0.8 |
Visit Page
|
| 60 |
Selinexor, daratumumab, and dexamethasone in patients with R/R multiple myeloma |
0.8 |
Visit Page
|
| 61 |
VRd superiority to lenalidomide, adriamycin, and dexamethasone (RAd) prior to risk-adapted transplant in newly diagnosed myeloma |
0.8 |
Visit Page
|
| 62 |
Phase III TOURMALINE-MM4 : Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma patients not undergoing ASCT |
0.8 |
Visit Page
|
| 63 |
DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with R/R multiple myeloma refractory to PI, IMiD, and anti-CD38 mAb |
0.8 |
Visit Page
|
| 64 |
BELLINI study : Evaluation of MRD in R/R multiple myeloma patients treated with venetoclax or placebo with Vd |
0.8 |
Visit Page
|
| 65 |
DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with Vd in R/R multiple myeloma |
0.8 |
Visit Page
|
| 66 |
First-in-human data of ALLO-501 and ALLO-647 in R/R LBCL/FL: ALPHA study |
0.8 |
Visit Page
|
| 67 |
Comparison of efficacy and safety with obinutuzumab plus chemo vs. rituximab plus chemo in patients with previously untreated FL: Updates from phase III Gallium Study |
0.8 |
Visit Page
|
| 68 |
First-line immunochemotherapy for FL in the GALLIUM study: Prognostic value of PET-CT status after long-term follow-up |
0.8 |
Visit Page
|
| 69 |
Bosutinib for CP-CML after imatinib failure: 8-year update |
0.8 |
Visit Page
|
| 70 |
Independent review: Arterial occlusive events due to ponatinib in PACE trial Ph+ CML |
0.8 |
Visit Page
|
| 71 |
Bosutinib in patients with chronic phase chronic myeloid leukemia intolerant to prior tyrosine kinase inhibitors: Analyses from the BYOND study |
0.8 |
Visit Page
|
| 72 |
KEYNOTE-204: Phase III study of Pembrolizumab vs Brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma |
0.8 |
Visit Page
|
| 73 |
HALO Trial: Brentuximab vedotin and bendamustine as first-line treatment of Hodgkin lymphoma in the elderly |
0.8 |
Visit Page
|
| 74 |
Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients. |
0.8 |
Visit Page
|
| 75 |
Gls-010 in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Impressive Phase II Results |
0.8 |
Visit Page
|
| 76 |
Long-term follow-up of anti-CD19 CAR T-cell therapy for B-cell NHL and CLL |
0.8 |
Visit Page
|
| 77 |
Safety and efficacy of optimized tandem CD19/CD20 CAR-engineered T cells in patients with R/R NHL |
0.8 |
Visit Page
|
| 78 |
Phase I/II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL |
0.8 |
Visit Page
|
| 79 |
Phase I study of AUTO3 with pembrolizumab in patients with r/r DLBCL |
0.8 |
Visit Page
|
| 80 |
Epcoritamab (GEN3013) to induce CR in pts with R/R B-NHL: Complete dose escalation data and efficacy results from a phase I/II trial |
0.8 |
Visit Page
|
| 81 |
Retreatment of pts with refractory DLBCL with axi-cel in ZUMA-1 |
0.8 |
Visit Page
|
| 82 |
Final results of Lenalidomide plus R-GDP (R2-GDP) - GOTEL in relapsed/refractory diffuse large B-cell lymphoma |
0.8 |
Visit Page
|
| 83 |
RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy in transplant-ineligible pts with R/R DLBCL |
0.8 |
Visit Page
|
| 84 |
Outpatient treatment with liso-cel across a variety of clinical sites from three ongoing clinical studies in R/R LBCL. |
0.8 |
Visit Page
|
| 85 |
Atezolizumab + obinutuzumab + venetoclax in patients with R/R DLBCL: Primary analysis of a phase II trial from LYSA |
0.8 |
Visit Page
|
| 86 |
Finally Opdivo in combination with Yervoy has got success in much awaited lucrative first line NSCLC patients whose tumors express PD-L1≥1% and approval is further supported by long term data |
0.8 |
Visit Page
|
| 87 |
Wthin a space of 11 days, Opdivo-Yervoy with chemo bagged another approval in first line NSCLC irrespective of PD-L1 expression |
0.8 |
Visit Page
|
| 88 |
Frontline durvalumab and tremelimumab combo misses overal survival endpoint in metastatic NSCLC |
0.8 |
Visit Page
|
| 89 |
Another new combination of tiragolumab and atezolizumab has shown efficacy signals in lucrative first line NSCLC |
0.8 |
Visit Page
|
| 90 |
Novartis unveils more capmatinib data from GEOMETRY mono-1 study |
0.8 |
Visit Page
|
| 91 |
Osimertinib trial results in NSCLC patients with EGFR exon 20 insertions from ECOG-ACRIN 5162 trial |
0.8 |
Visit Page
|
| 92 |
Roche presented long term data of alectinib from ALEX study in frontline advanced ALK+ NSCLC |
0.8 |
Visit Page
|
| 93 |
Another MET inhibitor expected to make their way in METex14+ mutated NSCLC |
0.8 |
Visit Page
|
| 94 |
Novartis presented the data from GEOMETRY mono-1 study to support the capmatinib usage in second line setting |
0.8 |
Visit Page
|
| 95 |
Takeda published brigatinib data from J-ALTA study to supprt its approval in Japanese patients |
0.8 |
Visit Page
|
| 96 |
Heat Biologics's allogeneic cellular vaccine in combination with nivolumab shown efficacy signals in phase I/II data |
0.8 |
Visit Page
|
| 97 |
Pembrolizumab usage along with radiothreapy associated with better efficacy outcomes |
0.8 |
Visit Page
|
| 98 |
Merck presented the data from VISION study to support its FDA approval in patients with NSCLC with METex14 skipping |
0.8 |
Visit Page
|
| 99 |
Two year follow up data of bintrafusp alfa presented by Merck with encouraging efficacy signals |
0.8 |
Visit Page
|
| 100 |
CheckMate 568 Part 2 data will further support the approval of nivolumab plus ipilimumab with two cycles of chemotherapy combo in firstline NSCLC setting |
0.8 |
Visit Page
|
| 101 |
Pegilodecakin did not show any improvement in efficacy when added to pembrolizumab in first line NSCLC |
0.8 |
Visit Page
|
| 102 |
Data from exploratory RELAY+ study of ramucirumab plus gefitinib supports its usage in first line EGFR mutated NSCLC |
0.8 |
Visit Page
|
| 103 |
Phase II study of venetoclax plus dose-adjusted R-EPOCH for Richter’s syndrome |
0.8 |
Visit Page
|
| 104 |
Good interim data from phase 2 trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC |
0.8 |
Visit Page
|
| 105 |
Initial results of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax |
0.8 |
Visit Page
|
| 106 |
Novartis presented Phase II data of one more promising irreversible 3rd-generation EGFR TKI |
0.8 |
Visit Page
|
| 107 |
TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions |
0.8 |
Visit Page
|
| 108 |
Acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL: ASCEND final results |
0.8 |
Visit Page
|
| 109 |
Final data of KEYNOTE-189 study in patients with newly diagnosed metastatic nonsquamous NSCLC |
0.8 |
Visit Page
|
| 110 |
Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib + trametinib in patients with BRAF V600E mutant metastatic NSCLC |
0.8 |
Visit Page
|
| 111 |
Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC |
0.8 |
Visit Page
|
| 112 |
Effect of adding ublituximab to ibrutinib on efficacy in previously treated high-risk CLL: GENUINE phase III study |
0.8 |
Visit Page
|
| 113 |
Some supporting data of Lorlatinib; irreversible 3rd-generation EGFR TKI in patients with ALK-positive NSCLC |
0.8 |
Visit Page
|
| 114 |
Mute response of Durvalumab trial as Durvalumab plus tremelimumab fails to show the clinical activity in patients with acquired resistance to PD-1 checkpoint inhibitors |
0.8 |
Visit Page
|
| 115 |
Acalabrutinib in treatment-naïve CLL: Mature results from Ph II study demonstrating durable remissions and longterm tolerability |
0.8 |
Visit Page
|
| 116 |
Fixed-duration venetoclax-obinutuzumab for previously untreated pts with CLL: Follow-up results from phase III CLL14 trial |
0.8 |
Visit Page
|
| 117 |
Supportive data from Nivolumab trial for its use as monotherapy or in combination with cisplatin/carboplatin and etoposide as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC) |
0.8 |
Visit Page
|
| 118 |
Phase III MURANO study results: Impact of premature venetoclax discontinuation/interruption on outcomes in R/R CLL |
0.8 |
Visit Page
|
| 119 |
Consistent result of tazemetostat in terms of Efficacy, safety, and immune priming effect in patients with epithelioid sarcoma. |
0.8 |
Visit Page
|
| 120 |
Eribulin and pembrolizumab disappointed with its efficacy results in Uterine leiomyosarcoma (LMS) |
0.8 |
Visit Page
|
| 121 |
Role of CDK4/6 inhibitors in treating advanced Soft Tissue Sarcoma (STS) |
0.8 |
Visit Page
|
| 122 |
Highest reported efficacy of doxorubicin + pembrolizumab till date in a preliminary advanced STS trial |
0.8 |
Visit Page
|
| 123 |
AKT inhibition by Ipatasertib in mCRPC: The A.MARTIN Randomized Phase II trial |
0.8 |
Visit Page
|
| 124 |
Updated results from ARAMIS phase III trial showed darolutamide improves overall survival (OS) over placebo in nmCRPC patients |
0.8 |
Visit Page
|
| 125 |
Updated overall survival results from PROSPER: A phase III, randomized, double-blind, placebo controlled study of enzalutamide (ENZA) in men with nmCRPC |
0.8 |
Visit Page
|
| 126 |
Apalutamide Plus ADT Leads to Significantly Improved Outcomes in Nonmetastatic CRPC: Results from the phase III SPARTAN trial |
0.8 |
Visit Page
|
| 127 |
Novel AKT inhibitor fails to demonstrate a difference in the primary outcome of PFS: Results from phase II ProCAID trial |
0.8 |
Visit Page
|
| 128 |
Pembrolizumab plus enzalutamide in patients with abiraterone acetate pretreated mCRPC: KEYNOTE-365 cohort C efficacy, safety, and biomarker results |
0.8 |
Visit Page
|
| 129 |
HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer |
0.8 |
Visit Page
|
| 130 |
Impact of Olaparib vs Physician’s Choice of New Hormonal Agent On Burden of Pain in mCRPC: Results from PROfound |
0.8 |
Visit Page
|
| 131 |
AstraZeneca presented the Health-related quality of life (HRQoL) data for olaparib versus enzalutamide or abiraterone in mCRPC with HRR gene alterations |
0.8 |
Visit Page
|
| 132 |
Exelixis reports data from Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With mCRPC |
0.8 |
Visit Page
|
| 133 |
Pfizer has presented the positive interim data of PARP inhibitor from the TALAPRO-1 phase II trial |
0.8 |
Visit Page
|
| 134 |
Data from CARD study Confirm Benefit of Cabazitaxel Over Abiraterone or Enzalutamide in mCRPC |
0.8 |
Visit Page
|
| 135 |
Much awaited result of Trastuzumab + trimodality treatment for HER2+ esophageal adenocarcinoma brought disappointment with its failure in reaching the primary end point |
0.8 |
Visit Page
|
| 136 |
No significant survival benefit of pembrolizumab over 2L paclitaxel in previusly treated PD-L1+ advanced gastric or gastroesophageal junction cancer |
0.8 |
Visit Page
|
| 137 |
Tumor mutational burden (TMB) demonstrates a positive association with clinical outcomes with pembrolizumab in gastric cancer |
0.8 |
Visit Page
|
| 138 |
Another PD-1 inhibitor (Sintilimab) jointly developed by Innovent and Eli Lilly has met its primary endpoint of overall survival in the second-line treatment of patients with metastatic esophageal squ... |
0.8 |
Visit Page
|
| 139 |
In gastric cancer no treatment till date has shown such a strong data, Definately Enhetru will be positioned much ahead of Kadcyla |
0.8 |
Visit Page
|
| 140 |
A rare failure of Olaparib brought a lot of disappointment for ovarian cancer patient community |
0.8 |
Visit Page
|
| 141 |
Role of DOCK8, EP 400, and PDX1 mutations as prognostic biomarkers & its association with longer survival in patients treated with Selinexor. |
0.8 |
Visit Page
|
| 142 |
Role of MDNA55 (Interleukin-4 Receptor) in a difficult to treat population (de novo GBM, IDH wild-type, not eligible for surgery at recurrence) & its benefit for patient resistant to temozolomide. |
0.8 |
Visit Page
|
| 143 |
Another novel combination approach (INO-5401 + INO-9012 with Cemiplimab) for newly diagnosed GBM patients |
0.8 |
Visit Page
|
| 144 |
Not so encouraging results for Atezolizumab in comination of Temozolomide for newly diagnosed GBM |
0.8 |
Visit Page
|
| 145 |
Savolitinib can be a better treatment choice than sunitinib due to its improved efficacy and safety profile |
0.8 |
Visit Page
|
| 146 |
Results from TIVO-3 supports use of Tivozanib for highly treatment refractory RCC patients |
0.8 |
Visit Page
|
| 147 |
Not very promising but Cabozantinib is an effective treatment option for the patients with advanced refractory RCC |
0.8 |
Visit Page
|
| 148 |
The result from KEYNOTE-426 warrants the use of pembrolizumab and axitinib as a standard of care for patients with previously untreated RCC |
0.8 |
Visit Page
|
| 149 |
Lenvatinib plus Pembrolizumab shows strong data for mccRCC with disease progression following prior PD-1/PDL-1 therapy |
0.8 |
Visit Page
|
| 150 |
Tumor Mutation Burden (TMB): One Size fits for all? Not really! |
0.8 |
Visit Page
|
| 151 |
Lilly overthrows Pfizer in Early HR+/HER2- Breast Cancer, what Next? |
0.8 |
Visit Page
|
| 152 |
ESMO 2020 – Major trials in focus and Our View Points |
0.8 |
Visit Page
|
| 153 |
Triumphs and Troubles for Combination Therapies in Melanoma: COMBI-I Trial Failure Story |
0.8 |
Visit Page
|
| 154 |
Will ADC’s be in focus in ESMO 2020 too? |
0.8 |
Visit Page
|
| 155 |
BMS/Exelixis face-off with Merck’s Keytruda in front-line renal cancer |
0.8 |
Visit Page
|
| 156 |
Gilead's ASCENT into Oncology: Sacituzumab results at ESMO 2020 |
0.8 |
Visit Page
|
| 157 |
ADAURA trial results presented at ESMO established proven clinical activity of Tagrisso (osimertinib) in the adjuvant treatment of early-stage EGFR-mutated lung cancer (EGFRm) |
0.8 |
Visit Page
|
| 158 |
ASCENT trial results establish Sacituzumab as new standard of care in third line for metastatic TNBC |
0.8 |
Visit Page
|
| 159 |
Promising results from the CROWN trial supports Lorbrena (lorlatinib) as a future first-line standard treatment in ALK+ NSCLC |
0.8 |
Visit Page
|
| 160 |
ESMO 2020: CheckMate 9ER Provides New First-Line Treatment Option for Patients Advanced RCC |
0.8 |
Visit Page
|
| 161 |
Head & Neck Cancers ESMO 2020 Insights |
0.8 |
Visit Page
|
| 162 |
Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatc... |
0.8 |
Visit Page
|
| 163 |
Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study |
0.8 |
Visit Page
|
| 164 |
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter,... |
0.8 |
Visit Page
|
| 165 |
Phase I/II study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer |
0.8 |
Visit Page
|
| 166 |
Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2- negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 random... |
0.8 |
Visit Page
|
| 167 |
Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) adva... |
0.8 |
Visit Page
|
| 168 |
PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer |
0.8 |
Visit Page
|
| 169 |
nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer |
0.8 |
Visit Page
|
| 170 |
Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic tripl... |
0.8 |
Visit Page
|
| 171 |
IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative bre... |
0.8 |
Visit Page
|
| 172 |
IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC) |
0.8 |
Visit Page
|
| 173 |
Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase... |
0.8 |
Visit Page
|
| 174 |
Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of th... |
0.8 |
Visit Page
|
| 175 |
Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004 |
0.8 |
Visit Page
|
| 176 |
Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238 |
0.8 |
Visit Page
|
| 177 |
Estimating long-term survivorship in patients with advanced melanoma treated with immune-checkpoint inhibitors: Analyses from the phase III CheckMate 067 trial |
0.8 |
Visit Page
|
| 178 |
First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study) |
0.8 |
Visit Page
|
| 179 |
LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours |
0.8 |
Visit Page
|
| 180 |
Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib) |
0.8 |
Visit Page
|
| 181 |
Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC |
0.8 |
Visit Page
|
| 182 |
Exploratory patient-reported outcomes among patients with RET-mutant medullary thyroid cancer in LIBRETTO-001: A phase I/II trial of selpercatinib (LOXO-292) |
0.8 |
Visit Page
|
| 183 |
POD1UM-201: A phase II study of retifanlimab (INCMGA00012) in advanced or metastatic Merkel cell carcinoma (MCC) |
0.8 |
Visit Page
|
| 184 |
Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL |
0.8 |
Visit Page
|
| 185 |
Phase 2 Trial of Lenvatinib + Pembrolizumab for Progressive Disease After PD-1/PD-L1 Immune Checkpoint Inhibitor in Metastatic Clear Cell Renal Cell Carcinoma: Results by Independent Imaging Review an... |
0.8 |
Visit Page
|
| 186 |
Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease |
0.8 |
Visit Page
|
| 187 |
A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic u... |
0.8 |
Visit Page
|
| 188 |
Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell c... |
0.8 |
Visit Page
|
| 189 |
Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma... |
0.8 |
Visit Page
|
| 190 |
Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial |
0.8 |
Visit Page
|
| 191 |
TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI) |
0.8 |
Visit Page
|
| 192 |
Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study |
0.8 |
Visit Page
|
| 193 |
Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastriccancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First result... |
0.8 |
Visit Page
|
| 194 |
Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study |
0.8 |
Visit Page
|
| 195 |
EMPOWER-Lung 1: Phase 3 first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% |
0.8 |
Visit Page
|
| 196 |
Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homol... |
0.8 |
Visit Page
|
| 197 |
HR+/HER2- Breast Cancer ESMO 2020 Insights |
0.8 |
Visit Page
|
| 198 |
PROfound Phase III trial results presented at ESMO established proven clinical activity of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 or ATM g... |
0.8 |
Visit Page
|
| 199 |
Highlights in Urothelial Carcinoma- ESMO 2020 |
0.8 |
Visit Page
|
| 200 |
ESMO 2020: Best of GI Cancers |
0.8 |
Visit Page
|
| 201 |
COSMIC-021: Another exceptional findings by Exelixis after the success of CheckMate -9ER study results |
0.8 |
Visit Page
|
| 202 |
ESMO 2020 – Ovarian Cancer Highlights |
0.8 |
Visit Page
|
| 203 |
ASCO 2021 Preview - Showstoppers in Gastric Cancers |
0.8 |
Visit Page
|
| 204 |
Amgen and Mirati – Leading Players With High Hopes for the Undruggable KRAS Mutation? |
0.8 |
Visit Page
|
| 205 |
We Have Got You Covered – Major Data Readouts at ASCO 2021 Annual Meeting |
0.8 |
Visit Page
|
| 206 |
ASC0 2021 Preview: Opdivo Boosting Relatlimab (LAG-3 Immunotherapy) Expected to Steal the Show? |
0.8 |
Visit Page
|
| 207 |
Triumph of Trop-2 in Antibody-Drug Conjugate (ADC) Space |
0.8 |
Visit Page
|
| 208 |
ASCO 2021 – MAGE-A4: Expectations from one of the most promising target in Oncology |
0.8 |
Visit Page
|
| 209 |
ASCO 2021-OlympiA Trial: Label Expansion of Lynparza Could Open New Commercial Opportunities |
0.8 |
Visit Page
|
| 210 |
Antibody Drug Conjugates Market Expansion: Steady Foothold in Cancer Treatment Through Significant Pacts |
0.8 |
Visit Page
|
| 211 |
Novartis’ Phase III VISION Study: Radio-ligand Therapy Heading for Regulatory Approval |
0.8 |
Visit Page
|
| 212 |
Day 1: ASCO 2021 Bladder Cancer Highlights |
0.8 |
Visit Page
|
| 213 |
Day 1: ASCO 2021 Cholangiocarcinoma Highlights |
0.8 |
Visit Page
|
| 214 |
Day 1 Highlights from Renal Cell Carcinoma (RCC) – ASCO 2021 |
0.8 |
Visit Page
|
| 215 |
Day 1 Highlights in Sarcoma - ASCO 2021 |
0.8 |
Visit Page
|
| 216 |
Day 1- ASCO 2021: Esophageal-Squamous Cell Carcinoma Highlights |
0.8 |
Visit Page
|
| 217 |
Day 1 Highlights in Breast Cancer- ASCO 2021 (Local/Regional/Adjuvant) |
0.8 |
Visit Page
|
| 218 |
Day 1 Highlights in Pancreatic Cancer- ASCO 2021 |
0.8 |
Visit Page
|
| 219 |
Day 1 Highlights from Lung cancer - ASCO 2021 |
0.8 |
Visit Page
|
| 220 |
Day 1 Highlights from Hematological cancer - ASCO 2021 |
0.8 |
Visit Page
|
| 221 |
Day 2 Highlights in Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer- ASCO 2021 |
0.8 |
Visit Page
|
| 222 |
Day 1-2 Highlights from Head and Neck Cancer (HNSCC) – ASCO 2021 |
0.8 |
Visit Page
|
| 223 |
Day 1-2 ASCO 2021 Colorectal Cancer Highlights |
0.8 |
Visit Page
|
| 224 |
Day 2 Highlights in Breast Cancer- ASCO 2021 |
0.8 |
Visit Page
|
| 225 |
Day 2 Highlights from Hematological cancer – ASCO 2021 |
0.8 |
Visit Page
|
| 226 |
Day 3 Nasopharyngeal Carcinoma Highlights ASCO21 |
0.8 |
Visit Page
|
| 227 |
Day 3 Glioblastoma Multiforme (GBM) - ASCO 2021 Highlights |
0.8 |
Visit Page
|
| 228 |
Day 3 Highlights from Lung cancer - ASCO 2021 |
0.8 |
Visit Page
|
| 229 |
Day 3 RCC Highlights ASCO 2021 |
0.8 |
Visit Page
|
| 230 |
ASCO 2021: Spotlight on Major Abstract in the Melanoma Segment |
0.8 |
Visit Page
|
| 231 |
Day 4 Highlights from Prostate Cancer - ASCO 2021 |
0.8 |
Visit Page
|
| 232 |
Day 4 Highlights from Hematological Cancers - ASCO 2021 |
0.8 |
Visit Page
|
| 233 |
Day 4 Highlights-Gynecological Cancer- ASCO 2021 |
0.8 |
Visit Page
|
| 234 |
Day 4- Nasopharyngeal cancer (NPC) Highlights: ASCO 2021 |
0.8 |
Visit Page
|
| 235 |
Day 4 - Colorectal Cancer ASCO 2021 Highlights |
0.8 |
Visit Page
|
| 236 |
Thyroid Cancer Highlights - ASCO 2021 |
0.8 |
Visit Page
|
| 237 |
Highlights from Melanoma - ASCO 2021 |
0.8 |
Visit Page
|
| 238 |
ESMO 2021 Preview: Margenza—a breast cancer drug—sets its niche in HER2 positive Gastric Cancer Space |
0.8 |
Visit Page
|
| 239 |
ESMO 2021 Preview: Lilly and Innovent’s Sintilimab all set to present its high phase results in Esophageal Squamous Cell Cancer and Gastroesophageal Adenocarcinoma |
0.8 |
Visit Page
|
| 240 |
Cheers to new headways in Oncology: Are you all ready for ESMO 2021 Annual Meeting? |
0.8 |
Visit Page
|
| 241 |
ESMO 2021 Preview: Merck now Moving Ahead with Welireg and Cabozantinib Combination in Advanced ccRCC, Post-Welireg’s Speedy Approval in VHL-associated RCC |
0.8 |
Visit Page
|
| 242 |
KRAS Players in ESMO 2021 – Mirati’s Adagrasib expected to Knockout Amgen’s much-hyped Lumakras in Colorectal Cancer: Can Toxicity Issues Ruin Mirati’s Plan? |
0.8 |
Visit Page
|
| 243 |
ESMO 2021 Preview: Daiichi and AstraZeneca’s Antibody Drug Conjugate (ADC) in advanced NSCLC |
0.8 |
Visit Page
|
| 244 |
ESMO 2021 Preview: Keytruda, already approved as a second-line treatment in Cervical Cancer, now eyeing first line setting |
0.8 |
Visit Page
|
| 245 |
Abstract LBA1: DS-8201– keeping up with a continuous need for newer options and better outcomes for Breast Cancer patients |
0.8 |
Visit Page
|
| 246 |
Bristol Myers Squibb to disclose data on Checkmate-651 trial evaluating Opdivo and Yervoy combination in frontline SCCHN after the regimen surprisingly fails to meet the primary endpoint |
0.8 |
Visit Page
|
| 247 |
Merck to present overall survival results from KEYNOTE-355 in frontline Triple-Negative Breast Cancer to further support accelerated approval received in late 2020 |
0.8 |
Visit Page
|
| 248 |
Evolving Landscape in First-Line HER2+ gastric cancer and gastro esophageal junction (GEJ) cancer |
0.8 |
Visit Page
|
| 249 |
ESMO 2021: Leap Therapeutics flags the potential in advanced first-line Gastroesophageal adenocarcinoma (GEA) |
0.8 |
Visit Page
|
| 250 |
ESMO 2021: Promising results of Ayala Pharma’s AL101 in Phase II ACCURACY trial for a rare form of cancer, Adenoid Cystic Carcinoma (ACC) |
0.8 |
Visit Page
|
| 251 |
ESMO 2021: Gritstone to advance its Neo-antigen Immunotherapy in Phase II/III metastatic, microsatellite-stable (MSS)-Colorectal Cancer (CC) |
0.8 |
Visit Page
|
| 252 |
ESMO 2021 Highlights: Sneak peek into some early phase results of Lung, Pancreatic, Prostate Cancer and others |
0.8 |
Visit Page
|
| 253 |
ESMO 2021: Merck provides first glimpse of combination activity of belzutifan and cabozantinib in advanced clear cell renal cell carcinoma (ccRCC). |
0.8 |
Visit Page
|
| 254 |
Merck’s Keytruda already carrying cervical cancer label in second-line, now spells a win in front-line setting with or without Avastin |
0.8 |
Visit Page
|
| 255 |
ZENITH20 (LBA46) Phase II trial shows positive results with Poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations |
0.8 |
Visit Page
|
| 256 |
ESMO 2021 Lung Cancer Highlights: Onboarding of Libtayo-Chemotherapy combo in first-line NSCLC. Should Merck worry? |
0.8 |
Visit Page
|
| 257 |
Glad tidings for the Chinese Biopharmaceuticals in the Gastro-intestinal (GI) cancer |
0.8 |
Visit Page
|
| 258 |
ESMO 2021: Post Tivdak’s successful approval in second line cervical cancer, the ADC now heading towards first-line setting as combination regimen |
0.8 |
Visit Page
|
| 259 |
ESMO 2021: Daiichi and AstraZeneca’s Antibody Drug Conjugates (ADCs) in early phase trials, post Enhertu’s outstanding success in breast cancer |
0.8 |
Visit Page
|
| 260 |
BMS’ LAG-3 and PD-1 inhibitor combo all set to fulfill high hopes in melanoma, post receiving priority review by the FDA |
0.8 |
Visit Page
|
| 261 |
Already approved as an adjuvant therapy in late stage melanoma, Merck’s Keytruda is now eyeing completely resected high-risk stage II melanoma patients (KEYNOTE-716) |
0.8 |
Visit Page
|
| 262 |
Exelixis excited to receive Cabometyx’s approval in radioiodine-refractory differentiated thyroid cancer (DTC) |
0.8 |
Visit Page
|
| 263 |
ASCO 2022: A Quick preview of Late-Breaking Abstracts (LBA) on Lung Cancer. Let’s not miss it! |
0.8 |
Visit Page
|
| 264 |
ASCO 2022 Preview Content for Breast Cancer |
0.8 |
Visit Page
|
| 265 |
ASCO 2022 Preview: Prostate Cancer |
0.8 |
Visit Page
|
| 266 |
ASCO 2022 Preview: Follicular Lymphoma |
0.8 |
Visit Page
|
| 267 |
ASCO 2022: A quick preview of key abstract on melanoma. Let’s not miss it! |
0.8 |
Visit Page
|
| 268 |
ASCO 2022: A Quick preview on Diffuse large B-cell lymphoma (DLBCL) |
0.8 |
Visit Page
|
| 269 |
ASCO 2022 PREVIEW: GYNECOLOGIC CANCER |
0.8 |
Visit Page
|
| 270 |
Cullinan Oncology’s CLN-081 demonstrates encouraging response in NSCLC patients with EGFR Exon 20 Insertion Mutations. |
0.8 |
Visit Page
|
| 271 |
Immutep's next-generation immunotherapy performs well in first-line NSCLC, offering some relief following the recent failure of the novel anti-TIGIT in lung cancer. |
0.8 |
Visit Page
|
| 272 |
Mirati’s Adagrasib overthrows Amgen’s Sotorasib and yielded a response rate of 43% in KRAS G12C mutation mNSCLC. Do first-mover advantage and safety give an edge to Sotorasib? |
0.8 |
Visit Page
|
| 273 |
Exelixis’ flagship product Cabozantinib demonstrated an ORR of 54% with 91% clinical benefit in Head and Neck Squamous Cell Carcinoma |
0.8 |
Visit Page
|
| 274 |
Roche’s Glofitamab, a CD20xCD3 bispecific mab, shows durable responses in R/R DLBCL in a pivotal phase II trial. Can Epcoritamab beat the CR rate of 39%? |
0.8 |
Visit Page
|
| 275 |
Braftovi shows a higher response rate in a triplet combination after adding Opdivo. Shifting focus towards microsatellite stable metastatic colorectal cancer (MSS CRC) patients. |
0.8 |
Visit Page
|
| 276 |
Closely watched Janssen and Legend Biotech's CAR-T cell therapy demonstrated durable responses in the earlier setting of Multiple Myeloma: Updated findings from the CARTITUDE-2 trial. |
0.8 |
Visit Page
|
| 277 |
Genmab/Abbvie’s Epcoritamab achieves a 100% response rate in patients with R/R follicular lymphoma (FL). Could safety issues be a concern? |
0.8 |
Visit Page
|
| 278 |
Gilead in trouble waters as Trodelvy shows below par response in 3L+ HR+/HER2- Breast Cancer Setting. Likelihood of a delayed launch and reduced market share? |
0.8 |
Visit Page
|
| 279 |
Daiichi’s Patritumab, its third ADC making headway in HER3 expressing metastatic Breast Cancer |
0.8 |
Visit Page
|
| 280 |
Enhertu carving out a new space for itself in HER2 low patients. A major-label expansion is likely on the way. |
0.8 |
Visit Page
|
| 281 |
Yet another failure in treating Small-Cell Lung Cancer as Roche's much-anticipated anti-TIGIT immunotherapy fails in Phase III |
0.8 |
Visit Page
|
| 282 |
Consistent results across all sub-groups seen in the newly launched first in class LAG-3 combination drug Opdualag |
0.8 |
Visit Page
|
| 283 |
Encouraging results of nivolumab + bevacizumab + FOLFOXIRI in patients with RAS/BRAF mutations as a 1st Line treatment option, Opportunity for BMS for further expanding its blockbuster label for CRC p... |
0.8 |
Visit Page
|
| 284 |
Merus’ Zenocutuzumab, a HER2-HER3 Bispecific Antibody, Successfully Targets NRG1 Fusions in Lung and Pancreatic Cancer |
0.8 |
Visit Page
|
| 285 |
Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its promise in Multiple Myeloma during ASCO 2022. |
0.8 |
Visit Page
|
| 286 |
Can Breyanzi be a hit CAR-T in second-line treatment after failing in the first-line setting for the patients with R/R Large B-cell lymphoma (LBCL)? |
0.8 |
Visit Page
|
| 287 |
The PROs further support Durvalumab + Chemo in becoming the new standard of care in 1st Line Advanced Biliary Tract Cancer, patients with high treatment unmet needs. |
0.8 |
Visit Page
|
| 288 |
Takeda’s flagship product panitumumab (PAN) + mFOLFOX6 versus bevacizumab (BEV) + mFOLFOX6 demonstrated better outcomes in primary endpoints for the Left-sided tumor population in metastatic colorecta... |
0.8 |
Visit Page
|
| 289 |
Making way for immunotherapy in the GI cancers, Durvalumab to become the new standard of care for advanced biliary tract cancers |
0.8 |
Visit Page
|
| 290 |
With modest efficacy, Neratinib continues to be a potential treatment option for HER2+ive biliary tract cancers. Puma Biotech to continue its search for more effective combination therapies. |
0.8 |
Visit Page
|
| 291 |
Is there enough opportunity in the competitive therapeutic landscape of Multiple Myeloma for new CAR-T cell therapies? Let's have a look at the promising results of early-stage CAR-T cell therapy pres... |
0.8 |
Visit Page
|
| 292 |
AbbVie’s telisotuzumab vedotin (Teliso-V) demonstrated encouraging responses in c-MET NSCLC patients who progressed on previous treatments. |
0.8 |
Visit Page
|
| 293 |
Daiichi’s novel HER3 ADC has shown to have a spark in HER3 NSCLC, post success in HER3 Breast Cancer trial. |
0.8 |
Visit Page
|
| 294 |
Junshi’s domestic Toripalimab’s significant results in recurrent or metastatic HNSCC. CRL issued on Nasopharyngeal Carcinoma could prove to be a setback? |
0.8 |
Visit Page
|
| 295 |
Sermonix’s Lasofoxifene, a potent oral SERM, emerges as a critical player in ESR1 mutated advanced HR+ breast cancer |
0.8 |
Visit Page
|
| 296 |
Mimivax’s SurVaxM improves survival time in newly diagnosed glioblastoma. A ray of hope flickers in deadly cancer. |
0.8 |
Visit Page
|
| 297 |
Novartis’s Tafinlar and Mekinist’s combo might receive a first-mover advantage in BRAF mutated Low-grade glioma. |
0.8 |
Visit Page
|
| 298 |
Is Paxalisib better than Temozolomide in the first-line setting? Approval seems quite challenging, though. |
0.8 |
Visit Page
|
| 299 |
With the emergence of Next-generation SERDs, Sanofi might hit the mark; however, competition seems tough |
0.8 |
Visit Page
|
| 300 |
Elranatamab exhibits a 60.6% ORR and a tolerable safety profile, according to new results from a planned interim analysis of the Phase II MagnetisMM-3 registration-enabling study. |
0.8 |
Visit Page
|
| 301 |
Sanofi’s ADC is targeting CEACAM5 in patients with NSCLC. CEACAM5 is expressed in 20% of patients with NSCLC adenocarcinoma. |
0.8 |
Visit Page
|
| 302 |
Performance of Veru Pharma’s Sabizabulin in Phase I/II mCRPC trial. Phase III VERACITY trial has already commenced. |
0.8 |
Visit Page
|
| 303 |
Is GSK's Jemperli giving hope that cancer can be cured? 100% Response rate is unbelievable. |
0.8 |
Visit Page
|
| 304 |
CEL-SCI Corporation presents first of its kind results for lower-risk advanced primary SCCHN population in 25+ years through its Phase III IT-MATTERS study. |
0.8 |
Visit Page
|
| 305 |
Rocky road for Next-generation SERDs and Dominance of Verzenio in Adjuvant Setting: ER+/HER2− Early Stage Breast Cancer Insights |
0.8 |
Visit Page
|
| 306 |
ESMO 2022 Preview: Metastatic Castration Resistant Prostate Cancer (mCRPC) |
0.8 |
Visit Page
|
| 307 |
Early stage results of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma |
0.8 |
Visit Page
|
| 308 |
AmMax Bio’s AMB-05X shows an optimal balance of safety and efficay in TSGCT patients |
0.8 |
Visit Page
|
| 309 |
Derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 mutations. |
0.8 |
Visit Page
|
| 310 |
Already established combination in refractory mCRC patients to show results in the front-line patients to capture market share |
0.8 |
Visit Page
|
| 311 |
Do tucatinib and trastuzumab have the potential to get the first mover advantage in HER2 positive mCRC? |
0.8 |
Visit Page
|
| 312 |
Can fruquintinib prove to be more beneficial than the best supportive care in colorectal cancer? |
0.8 |
Visit Page
|
| 313 |
AstraZeneca’s Triplet regimen (durvalumab + Olaparib + Bevacizumab) elicits excellent efficacy profile than doublet (olaparib plus durvalumab) in non gBRCA mutated (wild type), platinum-sensitive ovar... |
0.8 |
Visit Page
|
| 314 |
Clinical study evaluating intermittent relacorilant with nab-paclitaxel in pretreated ovarian cancer |
0.8 |
Visit Page
|
| 315 |
Postmarking clinical assessment of rucaparib vs. chemotherapy in advanced, relapsed patients with deleterious BRCA1/2 mutation in ovarian cancer |
0.8 |
Visit Page
|
| 316 |
Extended follow-up results of Phase I/II study of DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) in patients with advanced solid tumors (Lung Cancer, Esophageal Cancer, and Prostate Cancer) |
0.8 |
Visit Page
|
| 317 |
Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation from the KRYSTAL-1 study |
0.8 |
Visit Page
|
| 318 |
Amgen is attempting to expand into the CRC market with a cocktail of LUMAKRAS and VECTIBIX, however prior evidence indicates liver toxicity signals in Lung Cancer |
0.8 |
Visit Page
|
| 319 |
Beyond Adagrasib and Lumakras, Roche's GDC-6036's phase I data are also scheduled to be presented at ESMO 2022. |
0.8 |
Visit Page
|
| 320 |
Interim analysis of Phase III trial of Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2) |
0.8 |
Visit Page
|
| 321 |
Verzenio, an Eli Lilly CDK4/6 inhibitor, missed the statistical significance in the second interim overall survival analysis, but exhibited a favorable trend; all eyes are now on the final OS analysis... |
0.8 |
Visit Page
|
| 322 |
Data from the planned second interim overall survival (OS) analysis further support Trodelvy (sacituzumab govitecan) in HR+/HER2– metastatic breast cancer |
0.8 |
Visit Page
|
| 323 |
Confirmatory clinical OS results raising questions about the use of rucaparib in advanced Ovarian Cancer |
0.8 |
Visit Page
|
| 324 |
Safety and efficacy results for Phase III trial of a dual anti-HER2 regimen of pyrotinib plus trastuzumab and docetaxel compared with placebo plus trastuzumab and docetaxel in untreated HER2-positive... |
0.8 |
Visit Page
|
| 325 |
The combination of nivolumab with or without ipilimumab in R/M cervical cancer showed encouraging safety and efficacy results |
0.8 |
Visit Page
|
| 326 |
Efficacy results from Phase II (FIDES-01) study with FGFR2F or FGFRMA patients with advanced iCCA with A, ≥1 prior chemotherapy |
0.8 |
Visit Page
|
| 327 |
A Groundbreaking Study in Head and Neck Cancer to Improve Cure Rate by Adding new Treatment to SoC |
0.8 |
Visit Page
|
| 328 |
Talimogene laherparepvec (T-VEC) as neoadjuvant treatment plus surgery vs immediate surgery in patients with resectable stage IVM1a melanoma |
0.8 |
Visit Page
|
| 329 |
Naporafenib (LXH-254) combinations prove to exhibit favorable efficacy with a tolerable safety profile in NRAS-Mutant Unresectable/Metastatic Melanoma |
0.8 |
Visit Page
|
| 330 |
Clinical efficacy and safety analysis update of intermittent relacorilant with nab-paclitaxel in heavily pretreated ovarian cancer patients |
0.8 |
Visit Page
|
| 331 |
Cemiplimab in comparison with Investigator’s choice (IC) of chemotherapy in recurrent/metastatic cervical carcinoma |
0.8 |
Visit Page
|
| 332 |
AstraZeneca’s Triplet regimen (durvalumab + Olaparib + Bevacizumab) bested over olaparib plus durvalumab doublet regimen in critical clinical profile evaluation in ovarian cancer |
0.8 |
Visit Page
|
| 333 |
Adjuvant setting in RCC is a hard nut to crack, nivolumab + ipilimumab combo fails, whereas Keytruda leads |
0.8 |
Visit Page
|
| 334 |
Trastuzumab Deruxtecan (Enhertu), the first US FDA-authorized HER2-directed treatment, produces clinically significant tumor response in patients with HER2m NSCLC in the Phase II DESTINY-Lung02 study |
0.8 |
Visit Page
|
| 335 |
MEDI5752 plus chemotherapy doubled the duration of response among patients with treatment-naïve non-squamous NSCLC, according to findings from a phase Ib/II study |
0.8 |
Visit Page
|
| 336 |
The Keynote-412 trial displays statistically insignificant results for Pembrolizumab plus CRT in locally advanced head and neck squamous cell carcinoma |
0.8 |
Visit Page
|
| 337 |
Closely watched Lynparza, the first PARP inhibitor to enter the first-line metastatic castration-resistant Prostate Cancer (mCRPC) setting demonstrated superior clinical benefit over abiraterone alone |
0.8 |
Visit Page
|
| 338 |
Triplet combination of tremelimumab + durvalumab + chemotherapy (T + D + CT) generated long-term overall survival (OS) benefit in frontline patients with metastatic NSCLC |
0.8 |
Visit Page
|
| 339 |
Preliminary Phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients |
0.8 |
Visit Page
|
| 340 |
Initial results from the INSIGHT 2 study evaluating Tepotinib plus Osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib |
0.8 |
Visit Page
|
| 341 |
Results from the randomized Phase II study of amcenestrant versus endocrine treatment of physician’s choice in patients with endocrine-resistant ER+/HER2− advanced breast cancer (AMEERA-3) |
0.8 |
Visit Page
|
| 342 |
Already established combination in refractory mCRC patients to show results in the front-line patients to capture market share |
0.8 |
Visit Page
|
| 343 |
Data from Phase III CodeBreak200 study showed superior PFS of Lumakras over docetaxel in previously treated non-small cell lung cancer (NSCLC) patients |
0.8 |
Visit Page
|
| 344 |
A promising option for refractory patients expressing HER2+ tucatinib and trastuzumab have the potential to get the first mover advantage in mCRC |
0.8 |
Visit Page
|
| 345 |
FRESCO-2 is a global Phase III study evaluating the safety and efficacy of fruquintinib in heavily pretreated mCRC patients |
0.8 |
Visit Page
|
| 346 |
The clinical results of the DeFi trial of nirogacestat excels in adults with progressing desmoid tumors |
0.8 |
Visit Page
|
| 347 |
Initial Findings from the Phase II/III Trial of AL102 for Desmoid Tumor treatment (DT) |
0.8 |
Visit Page
|
| 348 |
Phase II Study of Belzutifan plus Cabozantinib as First-line Treatment of Advanced Renal Cell Carcinoma (RCC): Cohort 1 of LITESPARK-003 |
0.8 |
Visit Page
|
| 349 |
ASCO 2023 PREVIEW CONTENT FOR BREAST CANCER: GRIPPING INSIGHTS INTO BREAST CANCER |
0.8 |
Visit Page
|
| 350 |
ASCO 2023 PREVIEW CONTENT FOR NON-SMALL CELL LUNG CANCER (NSCLC) |
0.8 |
Visit Page
|
| 351 |
ASCO 2023: A Quick preview of Late-Breaking Abstracts (LBA) and Late Phase abstracts on Head and Neck Cancer |
0.8 |
Visit Page
|
| 352 |
Will the DESTINY-PanTumor02 trial serve to reinforce the potential of ENHERTU in treating a range of HER2-expressing cancers? |
0.8 |
Visit Page
|
| 353 |
Nivolumab plus chemotherapy as a postoperative adjuvant therapy for stage III G/GEJ Cancer fell short of meeting the primary endpoint. However, it stimulates contemplation and prompts deeper reflectio... |
0.8 |
Visit Page
|
| 354 |
IMerge: Promising Results of a Phase III Study Show Imetelstat's Potential in Transfusion-Dependent Non-del (5q) Lower-Risk Myelodysplastic Syndromes |
0.8 |
Visit Page
|
| 355 |
Novartis unveils groundbreaking results from the pivotal Phase III NATALEE trial in early breast cancer patients |
0.8 |
Visit Page
|
| 356 |
FELIX Study Validates Impressive Product Profile of Obe-cel: Efficacy and Safety in Perfect Harmony |
0.8 |
Visit Page
|
| 357 |
Can REBLOZYL become a potential new first-line standard of care (SoC) for transfusion-dependent, lower-risk myelodysplastic syndromes? |
0.8 |
Visit Page
|
| 358 |
A first-in-human study of CD123 NK Cell Engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia |
0.8 |
Visit Page
|
| 359 |
Elranatamab Sparks Remarkable Responses in Relapsed/Refractory Myeloma Patients Following BCMA Therapy |
0.8 |
Visit Page
|
| 360 |
Potent Responses Observed in Relapsed/Refractory Multiple Myeloma with Talquetamab Plus Daratumumab Combination Therapy |
0.8 |
Visit Page
|
| 361 |
Janssen's Dual Bispecific Combination Study Achieves Unprecedented 96% Overall Response Rate in Relapsed or Refractory Multiple Myeloma Patients |
0.8 |
Visit Page
|
| 362 |
Pfizer revealed the first-in-human data of potent and innovative CDK2-selective inhibitor PF-07104091 in advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer |
0.8 |
Visit Page
|
| 363 |
Next-Gen CDK4-Selective Inhibitor PF-07220060 shines in first-in-human Phase I/IIa study, unveiling impressive results for advanced solid tumors enriched with HR+ HER2- mBC patients who experienced pr... |
0.8 |
Visit Page
|
| 364 |
Improved outcomes in advanced ovarian cancer: LYNPARZA and IMFINZI combination reduces disease progression risk by 37% in DUO-O Phase III trial for patients without tumor BRCA mutations |
0.8 |
Visit Page
|
| 365 |
BCMA/CD19 dual-targeting GC012F demonstrates highly promising activity in RRMM including high-risk patients and heavily pretreated patients with prior exposure to anti-38 mAb, PI, IMIDs |
0.8 |
Visit Page
|
| 366 |
Luveltamab Tazevibulin provides significant clinical benefit for ovarian cancer patients, regardless of the varying levels of FolRα-expression heterogeneity |
0.8 |
Visit Page
|
| 367 |
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase IIb Trial Data of HERIZON-BTC-01 study Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers |
0.8 |
Visit Page
|
| 368 |
Oncolytics unveils groundbreaking findings from BRACELET-1 (PrE0113) trial, harnessing inflammatory phenotype in metastatic HR+/HER2- breast cancer with pelareorep, paclitaxel, and avelumab combinatio... |
0.8 |
Visit Page
|
| 369 |
Junshi Biosciences revealed the impressive findings from the Phase III trial of toripalimab versus placebo, in combination with nab-P for patients with metastatic or recurrent TNBC |
0.8 |
Visit Page
|
| 370 |
Ipsen presents the updated OS (overall survival) data for NALIRIFOX compared to Gem+NabP as a first-line therapy in patients with mPDAC. |
0.8 |
Visit Page
|
